**Prevention & Therapies for Hepatitis and Chronic Liver Disease**

**Richmond, VA – June 4, 2022**

| Conference Location | Delta Hotels by Marriott Richmond Downtown  
| 555 East Canal St  
| Richmond, Virginia | Phone: (804) 788-0900 |
| | [https://www.marriott.com/hotels/travel/ricde-delta-hotels-richmond-downtown](https://www.marriott.com/hotels/travel/ricde-delta-hotels-richmond-downtown) |

**Parking at the Seminar**
A reduced daily parking rate of $15 has been arranged for you. Please bring the parking ticket to the seminar registration desk to receive this rate.

**Driving Directions**
- From the Richmond International Airport
  - Take I-64 West toward I-95 Richmond for approximately 9 miles.
  - Take (Left) Exit 190 onto 5th Street toward Downtown/Coliseum/I-95 South/Petersburg.
  - Continue straight on 5th Street for .75 miles (about 9 city blocks.)
  - Turn Left onto Cary Street and continue 3 blocks. Turn Right on 8th Street and continue 1 block.
  - Turn Right onto Canal Street. Hotel entrance is 2 blocks ahead on the Left side of Canal Street.

**Seminar Agenda and Syllabus Information**
- The Emerging Therapies seminar is a paperless program. The course syllabus and related materials will be made available on a digital app that can be accessed by a smart phone, tablet device or personal computer. Instructions to download the App will be provided to participants in advance of the seminar. Wi-Fi will be available without charge.

### Pre-Program Activities

<table>
<thead>
<tr>
<th>Time</th>
<th>Activity</th>
</tr>
</thead>
<tbody>
<tr>
<td>7:00am</td>
<td>Registration and View Exhibits</td>
</tr>
<tr>
<td>7:30 am</td>
<td>Opening Comments and Pre-Test</td>
</tr>
</tbody>
</table>
| 7:45 am | Lecture 1 – Viral Hepatitis: A summary for discovery and natural history of HCV  
| 60 min | Lecture 2 - End Stage Liver Disease: An overview of Treatment, Managing Complications chronic liver disease, cirrhosis, and the transplant process  
| 45 min | Hepatitis C: Update on Diagnostics  
| | • Short recap of key points from Pre-course lecture on viral hepatitis  
| | • Screening and diagnostic approaches of HCV |
| | Hepatitis C: Update on Treatment  
| | • AASLD/IDSA Guidelines and Updates  
| | • Simplified Guidance |
| | Case Studies 1 and 2 – New Case relevant to diagnosis and treatment of high-risk HCV patient |
| 8:35 am | Anti-viral Therapies for HBV  
| | • Early detection and treatment approaches  
| | • Treating HCC in patients with Hepatitis B  
<p>| | • Reactivation of HBV |
| 9:05 am | Industry Presentation #1 Break and View exhibits |</p>
<table>
<thead>
<tr>
<th>Time</th>
<th>Session Title</th>
<th>Details</th>
</tr>
</thead>
</table>
| 10:15 am | Delta Hepatitis and Hepatitis E Update                                       | Worldwide perspective and promising research studies  
Real world outcome studies on HDV and HEV                                                                              |
| 10:45 am | End Stage Liver Disease: Recap and Clinical Case                             | A review of Pre-course lecture touching on staging, work-up and remedies for cirrhosis and the liver transplant process                  |
| 11:15 am | Alcoholic Liver Disease                                                      | The growing prevalence of alcohol over-consumption and its impact on liver health  
Warning signs and intervention in alcoholic hepatitis                                                                    |
| 11:45 am | Hepatocellular Carcinoma (HCC)                                                | Screening diagnostic serum assays and imaging tests  
Treatment and management options: Ablation, TACE and Surgery                                                              |
| 12:15 pm | Luncheon and Industry Presentation #2                                         |                                                                                                                                       |
| 1:00 pm   | Session 2                                                                    |                                                                                                                                       |
| 1:10 pm   | Hepatocellular Carcinoma: New Systemic Treatment Options                     | Current FDA-Approved Therapies  
New chemotherapy regimens in development and testing  
Immunotherapy as the new MoA for HCC  
Case Study 3– Diagnosis and Treatment of Hepatocellular Carcinoma                                                        |
| 1:40 pm   | SARS-COV-2 in Liver Disease                                                  | Effect of COVID on the liver and in cirrhotic patients  
COVID-19 challenges for liver transplant recipients                                                                           |
| 2:10 pm   | Primary Sclerosing Cholangitis (PSC) and Primary Biliary Cholangitis          | Epidemiology of PSC and Ursodiol and Antibiotic Treatments  
Predicting outcomes and Improving Survival in PSC patients  
Causes and Markers of PBC  
Ursodeoxycholic Acid (UDCA) and Obeticholic Acid                                                                            |
| 2:45 pm   |                                                                               |                                                                                                                                       |
| 3:00 pm   | NAFLD and NASH                                                               | Epidemiology, Demographics and Diagnosis  
Scoring, Staging and Management of Fatty Liver Disease  
Treatment options for thrombocytopenia; including alternatives to platelet transfusion.                                    |
| 3:35 pm   | NASH Treatments in Practice and in Development                              | Current therapies for NASH including Updates from AASLD and EASL  
Lifestyle changes as a therapy  
Drugs in clinical development for NASH                                                                                       |
| 4:25 pm   | Closing Comments, Post-test and Wrap-Up                                      |                                                                                                                                       |
| Post-program activities | Lecture 3 - Viral Hepatitis Updates: The reemergence of Hepatitis A and Overcoming barriers to liver health in special populations | 60 minutes                                                                                                                             |
**Attendance Policies**

**Attendee Cancellation, Substitution, Refund**
The course tuition is refundable, minus a $20 processing fee, if your cancellation is received in writing no later than seven days prior to the conference. Attendee substitutions are allowed, but notification must be made in writing seven days prior to the conference. After that date, no refunds, credits, or substitutions will be granted. No refunds or credits will be given to those who “no show.”

**Recording and Photography**
The University of Louisville reserves exclusive rights to record (audio and video) and/or photograph conference proceedings for use in marketing materials, future presentations and other purposes.

**Guest Attendance**
All conference activities (including educational sessions, meal functions, exhibit hall participation and others) are exclusively reserved for seminar participants. Non-registered guests (including children, family members, colleagues and others) are not permitted in the seminar areas.

**Conference Modification or Cancellation**
The University of Louisville and SC Liver Research Consortium reserve the right to modify the course’s schedule, faculty or content if necessary. They also reserve the right to cancel this seminar, and in the unlikely event, a full refund of the registration fee will be provided. We are unable to refund any travel costs (flight, hotel, etc.) in the case of a seminar cancellation.

---

**CME Information**

**Physicians (MD/DO)** - The University of Louisville Office of Continuing Medical Education & Professional Development designates this live activity for a maximum of 10.0 *AMA PRA Category 1 Credit(s)*™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

**Nurses** - This program has been approved by the Kentucky Board of Nursing for 12.0 continuing education credits through University of Louisville Hospital, provider number 4-0068-12-22-1264. The Kentucky Board of Nursing approval of an individual nursing education provider does not constitute endorsement of program content.

**Nurse Practitioners and Physician Assistants** - AANP and AAPA accept Category I credit from *AMA PRA Category 1 Credit(s)*™ organizations accredited by ACCME.
JASMOHAN S. BAJAJ, MBBS, MD, MS, FACG

Jasmohan S. Bajaj, MBBS, MD, MS, is a Tenured Professor of Medicine, Division of Gastroenterology, Hepatology, and Nutrition at Virginia Commonwealth University and McGuire VA Medical Center in Richmond, VA. He is a Fellow of the American Gastroenterological Association, American Association for the Study of Liver Disease and American College of Gastroenterology.

Active in research, Dr. Bajaj has served as a principal investigator or coinvestigator for numerous clinical trials in areas such as hepatic encephalopathy, chronic liver disease and microbiome. Dr Bajaj is an Associate Editor for the American Journal of Gastroenterology and Gut Microbes and is on the editorial board for the Journal of Hepatology, Hepatology and Liver Transplantation.

MITCHELL SHIFFMAN, MD

Mitchell L Shiffman, MD is the Director of the Liver Institute of Virginia, which includes the Bon Secours Liver Institute of Richmond and the Bon Secours Liver Institute of Hampton Roads, both of which are clinical practice within Bon Secours Mercy Health with offices in Richmond and Newport News, Virginia. He is also Professor of Medicine at the Eastern Virginia Medical School, Norfolk, Virginia.

At the Liver Institute of Virginia Dr Shiffman and his associates care for and manage patients with all forms of acute and chronic liver disease, including patients with hepatocellular carcinoma, patients with advanced cirrhosis awaiting liver transplantation and patients who have undergone liver transplantation.

SARAH HUBBARD, PA-C

Sarah Hubbard is a Physician Assistant at the Liver Institute of Virginia where she has over twenty years of experience in the management of chronic liver disease. She received her Bachelor of Medical Science, Physician Assistant degree from Saint Louis University, where she also completed a fellowship for advanced training in the care of liver disease for PAs.

Her clinical expertise has involved the development of successful treatment strategies and patient education material for patients undergoing therapy for viral hepatitis and NASH. Ms. Hubbard has spent her career in academic, private and community-based medical centers where she has been involved in clinical research trials and the education of physicians-in-training and nursing staff.